Business Context and Reporting Period
Aldeyra Therapeutics, Inc. (ALDX) filed a Form 8-K on April 1, 2026, reporting the termination of its Hercules Credit Facility. The Company is a Delaware corporation with principal executive offices in Lexington, MA.
Key Financial Metrics
- Debt Repayment: The Company paid off outstanding borrowings of $15 million on April 1, 2026.
- Facility Status: All outstanding commitments under the Hercules Credit Facility were terminated, and the facility expired on its maturity date.
- Liquidity: As of December 31, 2025, cash, cash equivalents, and marketable securities are expected to support operations into 2028.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Material Changes
The primary material change is the full repayment of the $15 million debt obligation and the subsequent termination of the Hercules Credit Facility, which was originally dated March 25, 2019, and matured on April 1, 2026.
Outlook and Management Commentary
Management indicated that the Company's existing cash, cash equivalents, and marketable securities as of December 31, 2025, are sufficient to fund operations through 2028. No specific risks, contingencies, or unusual items were detailed beyond the debt repayment event.
Investor Verification Points
- Confirm the exact balance of cash, cash equivalents, and marketable securities as of December 31, 2025, to validate the runway into 2028.
- Verify that no other debt obligations or credit facilities remain outstanding following the termination of the Hercules Credit Facility.
- Review the Company's burn rate and operational expenses to assess the sustainability of the projected 2028 liquidity horizon.